Immune Cell Interactions in Atherosclerosis
动脉粥样硬化中的免疫细胞相互作用
基本信息
- 批准号:10334090
- 负责人:
- 金额:$ 28.97万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-08-01 至 2022-06-02
- 项目状态:已结题
- 来源:
- 关键词:AddressAngiographyAnti-Inflammatory AgentsAntigensApolipoproteinsApolipoproteins BArterial Fatty StreakArteriesAtherosclerosisB-Lymphocyte SubsetsB-LymphocytesBlood VesselsCCR6 geneCD8-Positive T-LymphocytesCardiac Catheterization ProceduresCardiovascular DiseasesCardiovascular systemCause of DeathCell CommunicationCell physiologyCellsCholesterolChronicClinicalClinical DataClinical TrialsColchicineComplementCoronaryCoronary ArteriosclerosisDevelopmentDiseaseDoseEnrollmentEpitopesEventGenetic TranscriptionGoalsHost DefenseHumanImmuneImmune TargetingImmune responseImmune systemImmunityImmunoglobulin MImpairmentIncidenceInfectionInflammatoryInterleukin-1 betaInterventionLaboratoriesLeadLinkLipidsLipoproteinsLongitudinal cohortLow-Density LipoproteinsLymphocyteLymphoid TissueMeasuresMembrane MicrodomainsMetabolicMetabolismModelingMolecularMonoclonal AntibodiesMulti-Ethnic Study of AtherosclerosisMusMyelogenousMyeloid CellsNational Heart, Lung, and Blood InstituteNatureOutcomeOutcome StudyPatientsPatternPeptide Sequence DeterminationPeptidesPeripheral Blood Mononuclear CellPhase III Clinical TrialsPlacebosPlasmaPlayProductionProteinsReactionRegulationResearchRoleSeminalSignal TransductionT cell responseT-LymphocyteT-Lymphocyte SubsetsTestingTherapeutic immunosuppressionThrombosisTrainingUniversitiesVirginiaWorkX-Ray Computed Tomographyadaptive immune responseatherogenesisatheroprotectivebasecardiovascular risk factorcohortcoronary plaquecytokinedata sharingdisorder riskfollow-uphigh dimensionalityhuman subjectimmune functionimmunoregulationlymph nodesmacrophagemembermonocytemouse modelnatural antibodiesnovel therapeutic interventionoxidized lipidoxidized low density lipoproteinpreventprogramsreceptorresponsetranscriptome sequencing
项目摘要
Overall Abstract
Our PPG will test the hypothesis that the lipid and protein components of lipoproteins trigger innate and
adaptive immune responses that control human atherosclerosis. We will study the immune cell cross-talk that
occurs during human atherosclerosis progression. Immunity plays an important role in coronary artery disease
(CAD), as recent clinical trials have clearly demonstrated. However, these trials also taught us that systemic
treatments of the immune system, by their very nature, impair host defense. Thus, it is imperative to find new,
more specific interventions that modulate immune cell function in atherosclerosis, yet spare host defense. We
will study immune cells and plasma from human subjects from 3 well-characterized clinical cohorts, 1-our
existing CAVA cohort (Coronary Assessment at Virginia), where subjects are enrolled from the UVA cardiac
catheterization laboratory that undergo quantitative coronary analysis for disease quantification; 2-
Computerized Tomography (CT)-CAVA cohort, where subjects undergoing noninvasive CT angiography for
cardiovascular disease assessment in years 1 and 2 of the PPG renewal (baseline measures) will be followed
up at 3 years to allow for determination of coronary plaque progression and changes in markers of plaque
vulnerability, and 3- The Multi-Ethnic Study of Atherosclerosis (MESA), a large NHLBI-sponsored
longitudinal cohort that has been ongoing since 2000. In this synergistic program, Project 1 CD9+ Monocyte
and Macrophage Immune Functions in Atherosclerosis has identified new monocyte subsets expressing the
tetraspanin CD9, and will study how CD9 impacts metabolism and immune modulation of monocytes and
macrophages in CAD. Project 2 Cholesterol Regulation of Inflammatory Macrophages in Atherosclerosis will
study how specialized lipid raft signaling drives transcriptional and metabolic reprogramming in macrophages.
Project 3 Regulation of Atheroprotective IgM-producing B cells in Murine and Human Atherosclerosis will study
how CD24 and CCR6 on newly identified human B-1 cell subsets modulate atheroprotective IgM production.
Project 4 ApoB-Specific CD4 and CD8 T cells Exacerbate Atherosclerosis will identify and study
immunodominant human apolipoprotein B (apoB) epitopes to investigate how these activate CD4 and CD8 T
cell using mouse models to address mechanisms. An important synergistic aspect to our PPG is that it is highly
interactive, in that B cells, T cells, monocytes and macrophages communicate with each other in the artery wall
and in lymphoid tissues. Unique aspects of our program are the focus on studying human immune cells, the
link to biospecimens and clinical data from 3 complementary cardiovascular cohorts, the use of unbiased high
dimensional protein and RNA-sequencing at the single cell level for all human immune cells from the same
human subjects, and our ability to link all of our group’s discoveries with extensive clinical data on each
subject. The human studies are complemented by murine mechanistic models where applicable. The end
goal of our studies is to identify safe new therapeutic strategies targeting immune cell function to limit CAD.
总体摘要
我们的 PPG 将测试脂蛋白的脂质和蛋白质成分触发先天和
我们将研究控制人类动脉粥样硬化的适应性免疫反应。
免疫在人类动脉粥样硬化进展过程中发挥着重要作用。
(CAD),正如最近的临床试验所清楚证明的那样,但是,这些试验也告诉我们系统性的。
免疫系统的治疗本质上会损害宿主的防御能力,因此,必须找到新的、更有效的方法。
我们可以采取更具体的干预措施来调节动脉粥样硬化中的免疫细胞功能,同时避免宿主防御。
将研究来自 3 个特征明确的临床队列的人类受试者的免疫细胞和血浆,其中 1 个是我们的
现有的 CAVA 队列(弗吉尼亚冠状动脉评估),其中受试者是从 UVA 心脏病入组
进行定量冠状动脉分析以进行疾病量化的导管实验室;
计算机断层扫描 (CT)-CAVA 队列,其中受试者接受无创 CT 血管造影
将遵循 PPG 更新的第一年和第二年的心血管疾病评估(基线措施)
最多 3 年,可确定冠状动脉斑块进展和斑块标记物的变化
3- 动脉粥样硬化多种族研究 (MESA),一项由 NHLBI 赞助的大型项目
自 2000 年以来一直在进行的纵向队列。在这个协同计划中,项目 1 CD9+ 单核细胞
动脉粥样硬化中的巨噬细胞和巨噬细胞免疫功能已鉴定出表达
四跨膜蛋白 CD9,并将研究 CD9 如何影响单核细胞和免疫调节
CAD 中的巨噬细胞 项目 2 动脉粥样硬化中炎症巨噬细胞的胆固醇调节
研究专门的脂筏信号传导如何驱动巨噬细胞中的转录和代谢重编程。
项目 3 将研究小鼠和人类动脉粥样硬化中产生动脉粥样硬化 IgM 的 B 细胞的调节
新鉴定的人类 B-1 细胞亚群上的 CD24 和 CCR6 如何调节动脉粥样硬化 IgM 的产生。
项目 4 ApoB 特异性 CD4 和 CD8 T 细胞加剧动脉粥样硬化将鉴定和研究
免疫显性人载脂蛋白 B (apoB) 表位,以研究它们如何激活 CD4 和 CD8 T
我们的 PPG 的一个重要的协同方面是它具有高度的协同作用。
相互作用,B 细胞、T 细胞、单核细胞和巨噬细胞在动脉壁中相互通讯
我们项目的独特之处在于研究人类免疫细胞,即
链接到来自 3 个互补心血管队列的生物样本和临床数据,使用无偏高
对来自同一细胞的所有人类免疫细胞进行单细胞水平的三维蛋白质和 RNA 测序
人类受试者,以及我们将我们小组的所有发现与每个研究的广泛临床数据联系起来的能力
在适用的情况下,人类研究得到了小鼠机制模型的补充。
我们研究的目标是确定针对免疫细胞功能以限制 CAD 的安全新治疗策略。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Catherine C Hedrick其他文献
Catherine C Hedrick的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Catherine C Hedrick', 18)}}的其他基金
Neutrophil Development During Inflammation and Atherosclerosis
炎症和动脉粥样硬化期间中性粒细胞的发育
- 批准号:
10651786 - 财政年份:2021
- 资助金额:
$ 28.97万 - 项目类别:
Neutrophil Development During Inflammation and Atherosclerosis
炎症和动脉粥样硬化期间中性粒细胞的发育
- 批准号:
10270897 - 财政年份:2021
- 资助金额:
$ 28.97万 - 项目类别:
Neutrophil Development During Inflammation and Atherosclerosis
炎症和动脉粥样硬化期间中性粒细胞的发育
- 批准号:
10470240 - 财政年份:2021
- 资助金额:
$ 28.97万 - 项目类别:
2019 Atherosclerosis Gordon Research Conference and Gordon Research Seminar
2019年动脉粥样硬化戈登研究大会暨戈登研究研讨会
- 批准号:
9759445 - 财政年份:2019
- 资助金额:
$ 28.97万 - 项目类别:
Protective Role of Nonclassical Monocytes in Immunotherapies for Solid Cancers
非经典单核细胞在实体癌免疫治疗中的保护作用
- 批准号:
9899213 - 财政年份:2018
- 资助金额:
$ 28.97万 - 项目类别:
Protective Role of Nonclassical Monocytes in Immunotherapies for Solid Cancers
非经典单核细胞在实体癌免疫治疗中的保护作用
- 批准号:
9471276 - 财政年份:2018
- 资助金额:
$ 28.97万 - 项目类别:
Project 1: Regulation of CD9+ Monocyte & Macrophage Immune Functions in Atherosclerosis
项目1:CD9单核细胞的调控
- 批准号:
10334094 - 财政年份:2017
- 资助金额:
$ 28.97万 - 项目类别:
Immune Cell Interactions in Atherosclerosis
动脉粥样硬化中的免疫细胞相互作用
- 批准号:
10623039 - 财政年份:2017
- 资助金额:
$ 28.97万 - 项目类别:
Monocyte Subsets & Immunity in Mouse and Human Atherosclerosis
单核细胞亚群
- 批准号:
10188605 - 财政年份:2017
- 资助金额:
$ 28.97万 - 项目类别:
相似国自然基金
冠状小微血管超声微泡造影多灌注峰参量三维高时空分辨成像
- 批准号:12374444
- 批准年份:2023
- 资助金额:53 万元
- 项目类别:面上项目
基于超声造影血流灌注智能定量系统明确血管正常化“窗口期”提升肺癌免疫检查点抑制剂疗效的研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
超声造影评价SOCS3通过miRNAs靶向介导的自噬途径调控血管新生对缺血性脑卒中的作用研究
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
针对活体微血管成像的时空融合运动衬度X射线造影术
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
在超广角眼底血管荧光造影上自动化精确测量糖尿病视网膜病变的血管改变及其临床应用
- 批准号:81900863
- 批准年份:2019
- 资助金额:21.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Coronary plaque changes with statin and colchicine among people with high polygenic risk- a mechanistic pilot study
他汀类药物和秋水仙碱对高多基因风险人群的冠状动脉斑块变化——一项机制试点研究
- 批准号:
10736120 - 财政年份:2023
- 资助金额:
$ 28.97万 - 项目类别:
Development of an Innovative Material for Transcatheter Peripheral Embolization
经导管外周栓塞创新材料的开发
- 批准号:
10257659 - 财政年份:2021
- 资助金额:
$ 28.97万 - 项目类别:
Development of an Innovative Material for Transcatheter Peripheral Embolization
经导管外周栓塞创新材料的开发
- 批准号:
10513904 - 财政年份:2021
- 资助金额:
$ 28.97万 - 项目类别:
Development of Nanoneedle Array for Painless and Long-Term Sustained Intraocular Drug Delivery
开发用于无痛、长期持续眼内药物输送的纳米针阵列
- 批准号:
10673052 - 财政年份:2021
- 资助金额:
$ 28.97万 - 项目类别:
Retinal microvasculature as a predictor of neurodegeneration in multiple sclerosis
视网膜微血管作为多发性硬化症神经变性的预测因子
- 批准号:
10469365 - 财政年份:2020
- 资助金额:
$ 28.97万 - 项目类别: